Sind Arbeitsdokumente einer Arbeitsgruppe der Welt-Gesundheitsorganisation WHO zu innovativen Wegen der Finanzierung medizinischer Forschung illegal an Pharmakonzerne gelangt? Von Wikileaks enthüllte Dokumente deuten darauf hin.
Eine interne Arbeitsgruppe der Welt-Gesundheitsorganisation WHO befasste sich mit innovativen Wegen, medizinische Forschung zu finanzieren. Hintergrund ist auch der steigende Bedarf weniger entwickelter Staaten an Zugang zu bezahlbaren Medikamenten.
Von Wikileaks enthüllte Dokumente scheinen einem Bericht von „Intellectual Property Watch“ zufolge nun zu zeigen, dass interne Arbeitspapiere dieser WHO-Gruppe betroffenen Pharmakonzernen zur Verfügung standen, vermutlich über den Interessenverband Internationale Vereinigung der Pharmakonzerne (International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)).
Die Meldung vom 10. Dezember 2010 beginnt
„Confidential documents related to the World Health Organization Expert Working Group on innovative financing for research and development surfaced today, revealing the group’s thinking as well as pharmaceutical industry thinking about the WHO process. The documents immediately raised concern about possible undue access to the process by industry; the WHO told Intellectual Property Watch the industry group was not supposed to have the documents.
The documents appear to have come from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and include draft reports on innovative financing mechanisms from the working group as well as an analysis by the IFPMA on the reports’ contents. They were released on Wikileaks, a website that anonymously publishes sensitive documents“
Der zuständige WHO-Direktor betont, die Dokumente der Arbeitsgruppe seien nicht für den Pharma-Verband bestimmt gewesen und diesem auch nicht übergeben worden:
„IFPMA was not supposed to have working drafts of the expert working group in their possession and they were not given these documents,” said Precious Matsoso, director of Public Health Innovation and Intellectual Property (PHI) at the WHO, under whose auspices the expert working group falls.“
Die „Expert Working Group on R&D financing “ der Welt-Gesundheitsorganisation WHO arbeitet innerhalb der Abteilung ‚Public Health, Innovation and Intellectual Property‘. Ihre Aufgabe beschreibt sie
„This group will examine current financing and coordination of research and development, as well as proposals for new and innovative sources of funding to stimulate research and development related to Type II and Type III diseases and the specific R&D needs of developing countries in relation to Type I diseases.“
„The final report of the expert group will be presented to the Health Assembly in May 2010.“
weitere Informationen:
wikileaks / Artikel von ‚Intellectual Property Watch‘: Big Pharma caught spying on the WHO
wikileaks: Big Pharma inside the WHO: confidential analysis of unreleased WHO Expert Working Group draft reports, 8 Dec 2009 (mit Links zu den einzelnen Dokumenten auf mehreren Spiegeln von wikileaks)
WHO Expert Working Group on R&D financing
.
[via ATN 14.12.2010]